Most clinical drug regimens for irinotecan (CPT-11 [Camptosar]) have been empirically based on classic in vivo pharmacokinetic and pharmacodynamic considerations. We propose an alternative approach that attempts to
Hans Minderman, PhD
Advertisement
Articles by Hans Minderman, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies
2
Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer
3
How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?
4
SLN Surgery Omission Does Not Increase Radiotherapy Use in Breast Cancer
5